Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BRTX Biorestorative Therapies
3.140+0.010+0.32%
Close
02/03 16:00 ET
3.1400.0000.00%
Post Mkt Price 02/03 19:27 ET
High
3.320
Open
3.180
Turnover
61.23K
Low
2.910
Pre Close
3.130
Volume
19.52K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
BioRestorative Therapies (OTCMKTS:BRTXQ) Reaches New 12-Month High at $3.20
BioRestorative Therapies, Inc. (OTCMKTS:BRTXQ – Get Rating) reached a new 52-week high on Wednesday . The company traded as high as $3.20 and last traded at $3.13, with a volume of 1074 shares tradin
BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event
Melville, New York--(Newsfile Corp. - January 17, 2023) - BioRestorative Therapies (NASDAQ: BRTX) ("BioRestorative", "BRTX" or the "Company"), a clinical stage company focused on stem cell-based thera
BioRestorative Therapies (OTCMKTS:BRTXQ) Sets New 1-Year High at $2.83
BioRestorative Therapies, Inc. (OTCMKTS:BRTXQ – Get Rating)'s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $2.83 and last traded at $2.72, with a
BioRestorative Therapies (OTCMKTS:BRTXQ) Reaches New 1-Year High at $2.96
BioRestorative Therapies, Inc. (OTCMKTS:BRTXQ – Get Rating) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $2.96 and last traded at $2.84, with a vo
BioRestorative Therapies (OTCMKTS:BRTX) Earns Buy Rating From Analysts at Roth Capital
Roth Capital initiated coverage on shares of BioRestorative Therapies (OTCMKTS:BRTX – Get Rating) in a research report sent to investors on Wednesday, The Fly reports. The firm issued a buy rating an
BioRestorative Therapies Price Target Announced at $15.00/Share by Roth Capital
BioRestorative Therapies Price Target Announced at $15.00/Share by Roth Capital
BioRestorative Therapies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/07/2022 361.57% Roth Capital → $15 Initiates Coverage On → Buy 09/28/2022 84.63% Maxim Group → $6 Initi
Roth Capital Initiates Coverage On BioRestorative Therapies With Buy Rating, Announces Price Target of $15
Roth Capital analyst Jonathan Aschoff initiates coverage on BioRestorative Therapies (NASDAQ:BRTX) with a Buy rating and announces Price Target of $15.
Company Overview
More
Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The firm is developing the following scientific programs: brtxDISC, which offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures and ThermoStem, which involves the use of a cell-based, brown adipose tissue construct, treatment for metabolic disease, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. Its products are sold under the BRTX-100, ThermoStem and Stem Pearls trademarks. The company was founded on June 13, 1997 and is headquartered in Melville, NY.
CEO： Mr. Lance Alstodt
Market： NASDAQ
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet